- Home>
- Specialties>
- HIV/AIDS Clinical Care>
- Top Story
Top HIV/AIDS Stories of 2008
Some perspective on the year’s greatest successes and disappointments
Dear Readers,
As is true every year in HIV research, 2008 brought with it both dramatic progress and some significant failures. Certainly, our therapies have grown better and better, with virologic suppression now an achievable reality for virtually all patients, regardless of baseline stage of disease or degree of drug resistance. Our attempts at prevention, however, have continued to fail, most notably in the vaccine arena, where a once-promising adenovirus-based vaccine proved ineffective and possibly harmful. These failures have forced us to completely reconsider how we should approach HIV prevention, with a greater focus on antiretroviral therapy for both those with the virus and those at risk. In the next year, we can anticipate not only the usual incremental advances in treatment but also greater progress (and challenges) as therapy is made more broadly available to the developing world.
Here are our Top Stories for 2008:
Earlier HIV Treatment Is Gaining Momentum
Beyond Abacavir/3TC: Good News on First-Line Regimens
Newer Drugs Strikingly Effective When Given Together
Crash and Burn of HIV Vaccine Candidates
No Good News Yet on Anti-HIV Microbicides
HIV Incidence in the U.S.: New Methods Result in a Higher Estimate
Antiretroviral Rollout — Successes and Challenges
Rapid HIV Testing Is Not Without Its Flaws
Published in Journal Watch HIV/AIDS Clinical Care December 29, 2008
Your Remark:
To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.